133 related articles for article (PubMed ID: 9382155)
1. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation.
Jaar B; Denis A; Viron B; Verdy E; Chamma F; Siohan P; Mignon F
Am J Nephrol; 1997; 17(5):399-405. PubMed ID: 9382155
[TBL] [Abstract][Full Text] [Related]
2. Effects of hemodialysis and long-term erythropoietin treatment on protein C, and on free and total protein S.
Clyne N; Egberg N; Lins LE
Thromb Res; 1995 Oct; 80(2):161-8. PubMed ID: 8588193
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
[TBL] [Abstract][Full Text] [Related]
4. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients.
Taylor JE; Belch JJ; McLaren M; Henderson IS; Stewart WK
Kidney Int; 1993 Jul; 44(1):182-90. PubMed ID: 8355460
[TBL] [Abstract][Full Text] [Related]
5. Impact of human recombinant erythropoietin on plasminogen activator inhibitor, and protein C and S activity.
Steffensen G; Aunsholt NA
Am J Nephrol; 1996; 16(5):453-4. PubMed ID: 8886186
[No Abstract] [Full Text] [Related]
6. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
7. Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin.
Schiffl H
Int J Artif Organs; 1992 Jun; 15(6):343-8. PubMed ID: 1639525
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M
Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569
[TBL] [Abstract][Full Text] [Related]
9. [Activity of selected neutrophil enzymes of patients maintained on hemodialysis and treated with erythropoietin (rHu EPO)].
Sułowicz W; Hanicki Z; Lisiewicz J; Kopeć A; Kraśniak A; Kuźniewski M; Kopeć J; Sydor A
Pol Arch Med Wewn; 1991 Jun; 85(6):391-5. PubMed ID: 1896403
[TBL] [Abstract][Full Text] [Related]
10. [The effect of recombinant erythropoietin on candidicidal activity of polymorphonuclear leukocytes in hemodialyzed patients].
Bartůnková J; Sulková S; Cebecauer M
Cas Lek Cesk; 1995 Dec; 134(23):756-9. PubMed ID: 8599817
[TBL] [Abstract][Full Text] [Related]
11. [Recombinant human erythropoietin stimulates synthesis of fetal hemoglobin in patients with renal anemia treated by repeated hemodialysis].
Hanicki Z; Sułowicz W; Stepniewski M; Kuźniewski M; Kraśniak A; Kopeć J; Cieszkowska U; Solarska K
Pol Arch Med Wewn; 1991 Jun; 85(6):352-5. PubMed ID: 1716757
[TBL] [Abstract][Full Text] [Related]
12. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
13. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
Trkulja V
Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
[TBL] [Abstract][Full Text] [Related]
14. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
Tarng DC; Huang TP; Doong TI
Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
[TBL] [Abstract][Full Text] [Related]
15. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
[TBL] [Abstract][Full Text] [Related]
16. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis.
Tomura S; Nakamura Y; Tachibana K; Deguchi F; Ando R; Chida Y; Marumo F
Blood Purif; 1993; 11(6):370-7. PubMed ID: 8043258
[TBL] [Abstract][Full Text] [Related]
17. [Chemical structure, biotechnical production and clinical use of recombinant erythropoietin].
Fandrey JK; Jelkmann WE
Z Gesamte Inn Med; 1992 Jun; 47(6):231-8. PubMed ID: 1642021
[TBL] [Abstract][Full Text] [Related]
18. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
19. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
